Related Experiment Video

Updated: Feb 5, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.7K

[Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC]

Shuang Zhang1, Jingjing Liu1, Changliang Yang1

  • 1Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|September 3, 2018
PubMed

Insights

Immunotherapy shows promise for non-small cell lung cancer (NSCLC) with brain metastases, particularly in driver-negative patients lacking targeted gene mutations. Further research is needed to overcome current limitations and challenges in this specific patient group.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Brain metastasis is a frequent complication and cause of death in non-small cell lung cancer (NSCLC).
  • Tyrosine kinase inhibitors have improved outcomes for NSCLC patients with driver gene mutations, including those with brain metastases.
  • Effective treatments remain limited for NSCLC patients with brain metastases and negative driver gene status.

Purpose of the Study:

  • To review the current research progress of immunotherapy in NSCLC patients with brain metastases.
  • To specifically focus on the role of immunotherapy in driver gene-negative NSCLC patients with brain metastases.
  • To analyze existing research limitations and future challenges in this field.

Main Methods:

  • Literature review of recent research on immunotherapy for NSCLC with brain metastases.
  • Analysis of clinical trial data and published studies.
  • Synthesis of findings related to driver gene status and treatment response.

Main Results:

  • Immunotherapy has emerged as a significant treatment option for NSCLC, especially for driver gene-negative patients.
  • The efficacy of immunotherapy in NSCLC patients with brain metastases, particularly the driver gene-negative subset, is an area of growing interest.
  • Current research highlights both progress and unmet needs in treating this population.

Conclusions:

  • Immunotherapy represents a promising avenue for NSCLC patients with brain metastases, especially those who are driver gene-negative.
  • Further investigation is crucial to optimize immunotherapy strategies and address the limitations in treating this specific patient group.
  • Understanding the role of immunotherapy in driver gene-negative NSCLC with brain metastases is a key focus for future research and clinical application.
Keywords:
Brain metastasesDriver gene negativeImmune checkpoint inhibitorLung neoplasms

More Related Videos

Micro-drive Array for Chronic in vivo Recording: Drive Fabrication14:03

Micro-drive Array for Chronic in vivo Recording: Drive Fabrication

Published on: April 20, 2009

25.9K
Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

17.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K
Energy to Drive Translocation01:37

Energy to Drive Translocation

Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
2.8K
Positive, Negative, and Zero Work00:58

Positive, Negative, and Zero Work

Work is done on an object when energy is transferred to the object. In other words, work is done when a force acts on a body that undergoes a displacement from one position to another. By definition, the work done by a force is the integral of the force with respect to the displacement along its path. Forces can vary as a function of position, and displacements can occur along various paths between two points. The magnitude of a force multiplied by the cosine of the angle that the force makes...
22.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K